Reading, MA, United States of America

Klarisa Rikova

USPTO Granted Patents = 26 

 

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Klarisa Rikova of Reading, MA

Introduction: Klarisa Rikova is a prominent innovator based in Reading, Massachusetts, who has made significant contributions to the field of cancer research through her numerous patents. With a total of 25 patents to her name, Klarisa has demonstrated a deep commitment to developing effective treatments and diagnostic methods.

Latest Patents: Klarisa's latest patents include the development of anti-CUB domain-containing protein 1 (CDCP1) antibodies and antibody-drug conjugates. These innovative therapies are designed to target cancer cells, enhancing detection, diagnosis, and treatment efficacy for patients. The disclosures highlight her focus on advancing anti-cancer therapies, underscoring her dedication to improving patient outcomes.

Career Highlights: Throughout her career, Klarisa has worked with prestigious organizations such as Cell Signaling Technology, Inc. and Bluefin Biomedicine, Inc. Her experience in these companies has equipped her with the necessary skills and knowledge to spearhead groundbreaking innovations in the biomedical field.

Collaborations: Klarisa has collaborated with notable peers, including Ailan Guo and Anthony Paul Possemato, who share her vision of advancing cancer research. These collaborations have fostered an environment of innovation and discovery, leading to the development of cutting-edge therapeutics.

Conclusion: Klarisa Rikova is a leading figure in the biotechnology sector, with a robust portfolio of patents that reflect her innovative spirit. Her commitment to addressing critical health challenges through the development of anti-cancer therapies positions her as a key player in the pursuit of effective solutions for cancer treatment and diagnosis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…